Novo Nordisk's raised forecast fails to change the debate over its obesity business
- Posted on August 5, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
